Annals of Surgical Oncology

, Volume 23, Issue 8, pp 2715–2722 | Cite as

Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy

  • Heather J. Chalfin
  • Jen-Jane Liu
  • Nilay Gandhi
  • Zhaoyong Feng
  • Daniel Johnson
  • George J. Netto
  • Charles G. Drake
  • Noah M. Hahn
  • Mark P. Schoenberg
  • Bruce J. Trock
  • Andrew V. Scott
  • Steven M. Frank
  • Trinity J. Bivalacqua
Urologic Oncology

Abstract

Purpose

Perioperative blood transfusion (PBT) has been inconsistently associated with adverse outcomes. Bladder cancer patients are unique as they frequently undergo neoadjuvant chemotherapy (NAC) with resulting immunosuppression, which may be exacerbated by transfusion-related immunomodulation. We examined the effect of leukoreduced PBT on oncologic outcomes and perioperative morbidity in radical cystectomy (RC) patients who received NAC, quantifying exposure with a novel dose-index variable.

Methods

The Johns Hopkins Radical Cystectomy database was queried for patients who had undergone NAC followed by RC from 2010 to 2013. Overall, 119 patients had available PBT and survival data. A multivariable Cox model evaluated risk factors, including pathologic stage, Charlson Comorbidity Index, age, race, year of surgery, surgical margin status, PBT, and preoperative hemoglobin for bladder cancer-specific survival (CSS) and overall survival (OS). Logistic regression models determined factors that were independently associated with perioperative morbidity.

Results

Median follow-up was 7.8 months (range 0.2–41.8), and during follow-up there were 25 deaths and 21 cancer deaths. PBT significantly predicted OS (hazard ratio [HR] 1.26, 95 % confidence interval [CI] 1.07–1.49; p = 0.005), CSS (HR 1.32, 95 % CI 1.11–1.57; p = 0.002), and morbidity (odds ratio [OR] 1.67, 95 % CI 1.26–2.21; p = 0.004) in univariate analyses. In multivariable models, PBT was significantly associated with morbidity (OR 1.77, 95 % CI 1.30–2.39; p = 0.0002), but not OS or CSS. Intraoperative transfusion was associated with decreased OS and CSS, and increased morbidity, whereas postoperative transfusion was only associated with increased morbidity.

Conclusions

Intraoperative blood transfusion was associated with increased perioperative morbidity and worsened OS and CSS in patients undergoing RC who had NAC. Although PBT may be life-saving in certain patients, a restrictive transfusion strategy may improve outcomes.

Keywords

Overall Survival Bladder Cancer Charlson Comorbidity Index National Comprehensive Cancer Network Radical Cystectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

Trinity J. Bivalacqua received a grant from the Johns Hopkins Greenberg Bladder Cancer Institute.

Disclosure

Noah M. Hahn has undertaken bladder cancer consulting for Merck, Oncogenex, and BMS, and has received research funding from Oncogenex, Novartis, and Mirati. Bruce J. Trock was an expert witness for Rochon Genova, LLP, to interpret studies of bladder cancer. Charles G. Drake was a Bristol–Myers Squibb immunology consultant, received research support, and was a Pfizer, Co-Stimm, and Dentron immunology/oncology consultant. Trinity J. Bivalacqua was a consultant for TARIS Biomedical, and received grants from the National Institutes of Health, AUA Care Foundation, and Johns Hopkins Greenberg Bladder Cancer Institute. Heather J. Chalfin, Jen-Jane Liu, Nilay Gandhi, Zhaoyong Feng, Daniel Johnson, George J. Netto, Mark P. Schoenberg, Andrew V. Scott, and Steven M. Frank declare that they have no conflict of interest relevant to the manuscript.

References

  1. 1.
    Dresner SM, Lamb PJ, Shenfine J, et al. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol. 2000;26:492–7CrossRefPubMedGoogle Scholar
  2. 2.
    Shiba H, Ishida Y, Wakiyama S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg. 2009;13:1636–42CrossRefPubMedGoogle Scholar
  3. 3.
    Keller SM, Groshen S, Martini N, et al. Blood transfusion and lung cancer recurrence. Cancer. 1988;62:606–10CrossRefPubMedGoogle Scholar
  4. 4.
    Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365(26):2453–62CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Herbert PC, Wells G. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group [published erratum appears in N Engl J Med. 1999;340(13):1056] N Engl J Med. 1999;340(6):409–17.CrossRefGoogle Scholar
  6. 6.
    Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010;304(14):1559–67CrossRefPubMedGoogle Scholar
  7. 7.
    Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356(16):1609–19CrossRefPubMedGoogle Scholar
  8. 8.
    8) Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding [published erratum appears in N Engl J Med. 2013;368(24):2341]. N Engl J Med. 2013;368(1):11–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371(15):1381–91.CrossRefPubMedGoogle Scholar
  10. 10.
    Robertson CS, Hannay HJ, Yamal JM, et al: Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA. 2014;312(1):36–47CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:CD002042. doi: 10.1002/14651858.CD002042.pub3.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Goodnough LT, Bach RG. Anemia, transfusion, and mortality. N Engl J Med. 2001;345:1272–4CrossRefPubMedGoogle Scholar
  13. 13.
    Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993;328:1372–6CrossRefPubMedGoogle Scholar
  14. 14.
    Eickhoff JH, Andersen J, Laybourn C. Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. The Danish Breast Cancer Cooperative Group. Br J Surg. 1991;78:1358–61CrossRefPubMedGoogle Scholar
  15. 15.
    Blumberg N. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg. 1998;85:1163–4.PubMedGoogle Scholar
  16. 16.
    Niegisch G, Albers P, Rabenalt R. Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). Urol Oncol. 2014;32(7):966–74.CrossRefPubMedGoogle Scholar
  17. 17.
    Morgan TM, Barocas DA, Chang SS, et al. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013;31(6):871–7CrossRefPubMedGoogle Scholar
  18. 18.
    Gierth M, Aziz A, Fritsche HM, et al. The effect of intra- and postoperative allogenic blood transfusion on patients’ survival undergoing radical cystectomy for urothelial carcinoma of the bladder. World J Urol. 2014;32(6):1447–53CrossRefPubMedGoogle Scholar
  19. 19.
    Kluth LA, Xylinas E, Rieken M, et al. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2014;113(3):393–8CrossRefPubMedGoogle Scholar
  20. 20.
    Linder BJ, Frank I, Cheville JC, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 2013;63(5):839–45CrossRefPubMedGoogle Scholar
  21. 21.
    Sadeghi N, Badalato GM, Hruby G, et al. The impact of perioperative blood transfusion on survival following radical cystectomy for urothelial carcinoma. Can J Urol. 2012;19(5):6443–9PubMedGoogle Scholar
  22. 22.
    Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327–48CrossRefPubMedGoogle Scholar
  23. 23.
    Marcato PD, Favaro WJ, Duran N. Cisplatin properties in a nanobiotechnological approach to cancer: a mini-review. Curr Cancer Drug Targets. 2014;14(5):458–76.CrossRefPubMedGoogle Scholar
  24. 24.
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published erratum appears in N Engl J Med. 2003;349(19):1880]. N Engl J Med. 2003;349(9):859–66.CrossRefPubMedGoogle Scholar
  25. 25.
    Gandhi NM, Baras A, et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: predicting response and assessing outcomes. Urol Oncol. 2015;33(5):204.e1-7CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lannan KL, Sahler J, Spinelli SL, Phipps RP, Blumberg N. Transfusion immunomodulation: the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis. 2013;50:61–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Fergusson D, Khanna MP, Tinmouth A, Hebert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth. 2004;51:417–24.CrossRefPubMedGoogle Scholar
  28. 28.
    van de Watering L. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion. 2007;47:1946. author reply 7–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Friese RS, Sperry JL, Phelan HA, Gentilello LM. The use of leukoreduced red blood cell products is associated with fewer infectious complications in trauma patients. Am J Surg. 2008;196:56–61.CrossRefPubMedGoogle Scholar
  30. 30.
    Abel EJ, Linder BJ, et al. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol. 2014;66(6):1139–47.CrossRefPubMedGoogle Scholar
  31. 31.
    Moschini M, Dell’Oglio P, et al. Effect of allogeneic intraoperative blood transfusion on survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: results from a single high-volume institution. Clin Genitourin Cancer. 2015;13(6):562–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Eldefrawy A, Soloway MS, Katkoori D, et al. Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: the likelihood of initiation and completion. Indian J Urol. 2012;28(4):424–6.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    National Comprehensive Cancer Network. Bladder cancer (version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
  34. 34.
    Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34(6):1608–16CrossRefPubMedGoogle Scholar
  35. 35.
    Glance LG, Dick AW, Mukamel DB, et al. Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery. Anesthesiology. 2011;114(2):283–92CrossRefPubMedGoogle Scholar
  36. 36.
    Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and blood transfusion in the critically ill–current clinical practice in the United States. Crit Care Med. 2004;32(1):39–52CrossRefPubMedGoogle Scholar
  37. 37.
    Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;1:CD005033. doi: 10.1002/14651858.CD005033.pub2.PubMedGoogle Scholar
  38. 38.
    Harrell FE, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Heather J. Chalfin
    • 1
  • Jen-Jane Liu
    • 1
  • Nilay Gandhi
    • 1
  • Zhaoyong Feng
    • 1
  • Daniel Johnson
    • 1
  • George J. Netto
    • 1
  • Charles G. Drake
    • 1
  • Noah M. Hahn
    • 1
  • Mark P. Schoenberg
    • 1
  • Bruce J. Trock
    • 1
  • Andrew V. Scott
    • 1
  • Steven M. Frank
    • 1
  • Trinity J. Bivalacqua
    • 1
  1. 1.James Buchanan Brady Urological InstituteThe Johns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations